| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
BF738735 (Compound 1) exhibits a substantial inhibitory effect on PI4KIIIβ activity in vitro, with an IC50 of 5.7 nM. PI4KIIIα is also harmed by BF738735, however not until 300 times greater concentrations (IC50 of 1.7 μM) are reached. Furthermore, BF738735's activity was examined using a panel of 150 cellular kinases, including 13 lipid kinases at a 10 μM dose. In vitro inhibition of PI4KIIIβ is unique to BF738735, as evidenced by inhibition rates for all kinases being less than 10%. With 50% effective doses ranging from 4 to 71 nM, BF738735 has broad-spectrum antiviral action and inhibits all enterovirus and rhinovirus species tested. All viruses examined were successfully suppressed by BF738735, with EC50 values ranging from 4 to 71 nM. Analyzed concurrently with EC50 and under identical culture circumstances for a duration of 3 to 4 days, BF738735 demonstrated lower cytotoxicity, with CC50 values varying between 11 and 65 μM, culminating in a notable selectivity index. Low BF738735 concentrations decreased luciferase levels to the GuaHCl treatment level, suggesting that BF738735 inhibits the replication of viral RNA. In this experiment, BF738735's EC50 of 77 nM is similar to the inhibition seen in a multicycle assay for coxsackievirus serotype B3 (CVB3) [1].
|
|---|---|
| ln Vivo |
Good plasma levels of antiviral medications were present in the samples, and BF738735 was well tolerated. At the 25 mg/kg dose, full inhibition was seen, while at the 5 mg/kg dose, some inhibition was noted [2].
|
| References |
| Molecular Formula |
C21H19FN4O3S
|
|---|---|
| Molecular Weight |
426.463966608047
|
| Exact Mass |
426.116
|
| CAS # |
1436383-95-7
|
| PubChem CID |
135742054
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.672
|
| LogP |
2.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
690
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IMHZCCZYPHJVMS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19FN4O3S/c1-13-19(15-6-7-18(27)17(22)11-15)26-9-8-23-20(21(26)25-13)24-12-14-4-3-5-16(10-14)30(2,28)29/h3-11,27H,12H2,1-2H3,(H,23,24)
|
| Chemical Name |
2-fluoro-4-[2-methyl-8-[(3-methylsulfonylphenyl)methylamino]imidazo[1,2-a]pyrazin-3-yl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~293.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3449 mL | 11.7244 mL | 23.4489 mL | |
| 5 mM | 0.4690 mL | 2.3449 mL | 4.6898 mL | |
| 10 mM | 0.2345 mL | 1.1724 mL | 2.3449 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
